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There has been a substantially increased interest in biomedical research impact assessment over the past 5 years. This can be studied
by a number of methods, but its influence on clinical guidelines must rank as one of the most important. In cancer, there are 43 UK
guidelines (and associated Health Technology Assessments) published (up to October 2006) across three series, each of which has
an evidence base in the form of references, many of which are papers in peer-reviewed journals. These have all been identified and
analysed to determine their geographical provenance and type of research, in comparison with overall oncology research published in
the peak years of guideline references (1999–2001). The UK papers were cited nearly three times as frequently as would have been
expected from their presence in world oncology research (6.5%). Within the United Kingdom, Edinburgh and Glasgow stood out for
their unexpectedly high contributions to the guidelines’ scientific base. The cited papers from the United Kingdom acknowledged
much more explicit funding from all sectors than did the UK cancer research papers at the same research level.
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It is increasingly being recognised that the quantitative evaluation
of biomedical research cannot depend only on the counting of
citations in the serial literature. They may measure academic
influence, but the funders of such research are usually more
concerned to see if it has had a practical benefit, especially to
patients. One of the ways in which research can influence practice
is through its contribution to the evidence base supporting clinical
guidelines (Heffner, 1998; Gralla et al, 1999; Connis et al, 2000;
Van Wersch and Eccles, 2001; Aldrich et al, 2003). These are
increasingly being used across many countries in the routine
clinical care of cancer patients. Most of them are published by
national professional medical associations (e.g., Rizzo et al, 2002;
Atwood et al, 2004; Makuuchi and Kokudo, 2006), but some are
developed by governmental bodies (e.g., Pogach et al, 2004).
It is normal for such guidelines to have lists of references that
comprise their evidence base. However, the quality of the evidence
is sometimes doubtful (Ackman et al, 2000; Watine, 2002; Burgers
and van Everdingen, 2004), and schemes have been devised to
grade the quality of the clinical trials, which form a large part of
the evidence base (e.g., Psaty et al, 2000; Liberati et al, 2001;
Michaels and Booth, 2001; Hess, 2003; Guyatt et al, 2006). Even
when the guidelines have been published, they are sometimes
criticised as inadequate (Jacobson, 1998; Norheim, 1999; Walker,
2001), insufficient (Toman et al, 2001) or they may become
outdated (Shekelle et al, 2001). There is also the question of
whether the guidelines will actually be followed in clinical practice
(Grol, 2001; Butzlaff et al, 2002; Bonetti et al, 2003; Bloom et al,
2004). The breadth of oncology practice (both patients and
treatment modalities), the rapid evolution of new treatments and
the often diverse interpretation of ‘evidence’ by health-care
professionals mean many patients are treated with hospital-
specific protocols rather than national guidelines. This situation
is particularly acute in certain site-specific cancers, for example,
lung (Sambrook and Girling, 2001).
A further cause of disagreement is the question of cost: a new
drug may be clinically effective and better than existing drugs or a
placebo, but so costly that an equivalent or greater health gain may
be achievable by other means, for example, better screening to
detect the disease at an early stage. This can cause considerable
dissension and lead to lawsuits to make the drug available for
particularly articulate patients (Dyer, 2006a), or from companies
and patients’ advocacy groups, which sometimes receive their
subsidies (Dyer, 2006b). Lobbying of the UK National Institute for
Health and Clinical Excellence (NICE) by pharmaceutical firms is
now rife (Ferner and McDowell, 2006), and a US politician has
adopted bully-boy tactics in his efforts to subvert evidence-based
medicine (Kmietowicz, 2006). The cost basis of NICE’s recom-
mendations has also been criticised: the figure of d30000 (h40000,
$60000) per quality-adjusted life year appears not to have a
scientific basis or to take account of the social costs of disease
(Collier, 2008).
Despite all these criticisms, clinical guidelines are nevertheless
gaining increasing recognition as the way forward. It does,
therefore, seem worthwhile to treat them as an outcome indicator,
even though a partial one, of the clinical impact of the research
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sthey cite. Several studies have analysed the evidence base of
selected clinical guidelines (Grant, 1999; Grant et al, 2000; Lewison
and Wilcox-Jay, 2003). They have established that the papers cited
are very clinical (when positioned on a scale from clinical
observation to basic research); that the UK guidelines overcite
the UK research papers; and that the cited papers are quite recent,
with a temporal distribution comparable to that of the papers cited
on biomedical research papers. Research from other European
countries seems to be cited about as much as would be expected on
the UK clinical guidelines, but that from Japan and from most
developing countries is almost totally ignored.
In this study, we examined three sets of the UK guidelines on a
single subject, cancer, and the references on 43 different guide-
lines, almost all concerned with treatment rather than with
prevention. The bibliographic details of the references were
assembled in a file and compared with those of cancer research
publications in the three peak years (1999–2001). The objective
was to answer several policy-related questions:
  how do countries’ relative presences among the cited references
compare with their presences in cancer research?
  how many of the cited references are actually classifiable as
cancer research?
  what is the research level (RL) distribution of these cited
references compared with that of cancer research papers?
  are the cited references published in journals of high citation
impact?
  how does the funding of the cited papers compare with that of
cancer research overall?
The latter two questions need to take account of the finding that
the references on clinical guidelines are much more clinical than
other biomedical research.
MATERIALS AND METHODS
UK cancer guidelines and the analysis of their references
There are three sets of clinical guidelines commonly used in the
United Kingdom:
  Published by the British Medical Association in Clinical
Evidence. This takes the form of a book that is revised and
extended every 6 months, but is also accessible on the Web (to
people in the United Kingdom);
  Developed by the National Institute for Health and Clinical
Excellence (NICE) for the National Health Service (NHS) in
England and Wales, based on Health Technology Assessments
(HTAs). Most of these last are available on the Web, but not all
(although it is intended by NICE that they should be). They were
used in the present study, because the references on the actual
guidelines were usually not visible;
  Developed by the Scottish Intercollegiate Guidelines Network
(SIGN) for use by the NHS in Scotland. All these are freely
available on the Web
Only a minority of these guidelines and HTAs are applicable to
cancer. The numbers are, respectively, 15, 18 and 10. Each of these
43 documents has a set of references, most of which are articles in
peer-reviewed journals. A total of 3217 references were found and
their details downloaded to file. Their addresses were parsed by
means of a special macro so that the integer and fractional counts
of each country were listed for each paper (a paper with two
addresses in the United Kingdom and one in France would count
unity for each on an integer count basis, but 0.67 for the United
Kingdom and 0.33 for France using fractional counting). The RL of
each paper was determined using the new system developed by
Lewison and Paraje (2004), in which each journal is assigned an RL
based on the presence of ‘clinical’ and ‘basic’ words in the titles of
papers it has published on a scale from 1¼clinical to 4¼basic. In
addition, the RL of groups of individual cited papers could be
calculated with reference to their individual titles, and the presence
of ‘clinical’ or ‘basic’ words within them. The potential citation
impact (PCI) of each cited paper was also determined with
reference to a file of Journal Expected Citation Rates provided by
Thomson Scientific (London, UK). This gave the mean number of
citations for papers published in a journal in a given year and cited
in the year of publication and the 4 subsequent years.
Funding data for virtually all the UK papers (790 out of 796)
were obtained from inspection of the acknowledgements to their
funding sources in the British Library. Many of the papers had
previously been looked up for the Research Outputs Database
(Webster et al, 2003) or for other projects, and only 151 needed to
be sought anew. The main comparator used to normalise the
results of the analysis of the cited references was a file of world
oncology research papers (Cambrosio et al, 2006). For the years
1999–2001, there were over 100000 such papers, and their
characteristics were used to see how the cited references compared
with them, with due account being taken of the differences
expected in mean RLs (the cited references being more clinical
than oncology papers overall).
RESULTS
Time and research level distributions
Figure 1 shows the distribution of the 3217 cited references by
publication date. There is a clear peak in the year 2000, and 31% of
all the references were published in the 3 years, 1999–2001, so this
was the time period used for many of the comparisons with world
oncology research.
Of the references classed as ‘articles’ or ‘reviews’, 88% were
within the subfield of oncology as defined by Cancer Research UK
(Cambrosio et al, 2006). This percentage remained sensibly
constant over the period, 1994–2004. However, the references
were in much more clinical journals than world oncology papers
for the year 2000, the peak year for the numbers of references, see
Figure 2. This result was obtained earlier (Grant et al, 2000;
Lewison and Wilcox-Jay, 2003) but with a much simplified (and
less accurate) method of categorisation of journals by RL. Of the
3217 papers, 2747 titles (86%) had either a ‘clinical’ or a ‘basic’
keyword, and the mean RL was 1.07, which is very close to the
lower end of the scale (RL¼1.0), and much below the mean RL
based on all the papers in the individual journals (RL¼1.43). This
shows that the references were being published in journals that
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Figure 1 Time distribution of the 3217 references on the UK cancer
clinical guidelines.
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reinforces the message that the papers were, therefore, almost
entirely clinical observation.
Geographical analysis
The presence of 20 leading countries in oncology research for 2000
and in the references from the clinical guidelines is shown in
Table 1, where the data have been shown on a fractional count
basis. Figure 3 presents the ratio between a country’s presence in
the guideline references and its presence in oncology research, that
is, the values shown in the last column of Table 1. As would be
expected, the UK oncology research is cited more than expected
from its presence in world oncology by a factor of almost 3, but
several other European countries’ work is also relatively overcited,
notably that of Denmark, Ireland and Sweden. Although Italy,
which is strong in clinical trials, shows to advantage, Germany is
relatively much undercited compared with its presence in cancer
research in recent years. Japanese work is almost ignored, but it is
likely that the Science Citation Index, where most of the references
were found, does not cover Japanese clinical journals. This,
however, is only a small part of the reason for the paucity of
Japanese references.
Within the United Kingdom, certain cities showed relatively to
advantage in terms of their percentage presence within the
fractional UK total of 605 papers cited by the guidelines,
compared with that in the 2332 UK oncology papers published
in 2000. The analysis is conveniently carried out on the basis of
postcode area, the first one or two letters of the UK postcode
system, for example, B¼Birmingham, CB¼Cambridge. Figure 4
shows a scatter plot for the 26 leading areas (out of 124),
accounting for about two-thirds of both totals. The spots above the
diagonal line represent areas that are more frequently cited than
expected, and vice versa. Among the former, EH¼Edinburgh and
G¼Glasgow are prominent, in part because the SIGN guidelines
overcite Scottish research papers, together with SM¼Sutton and
Cheam (the location of the Institute of Cancer Research) and
OX¼Oxford.
Table1 and Figure 3 show overall values, but an analysis can also
be made of subsets of papers for groups of 2 or 3 years, chosen so
that the four periods each have about 20% of the total cited
references, see Table 2. For nearly all the countries, there are close
similarities between the time trends, which suggest that the
guidelines are rather consistent in the geography of their citing
behaviour. Thus, Australia, Canada, Sweden, the United Kingdom
Table 1 The fractional count outputs of 20 countries in oncology research in 2000 and in the references on the 43 UK cancer clinical guidelines and
HTAs, their percentage presences and the ratio of the two percentages
Country ISO Oncology research Guideline references Oncology references, % Guideline references, % Ratio
Australia AU 552 94 1.5 3.0 1.93
Austria AT 402 25 1.1 0.8 0.69
Belgium BE 353 47 1.0 1.5 1.51
Canada CA 1056 143 2.9 4.5 1.53
Switzerland CH 410 33 1.1 1.0 0.90
Germany DE 2736 133 7.6 4.2 0.55
Denmark DK 256 45 0.7 1.4 1.99
Spain ES 646 46 1.8 1.4 0.80
Finland FI 317 25 0.9 0.8 0.91
France FR 1749 198 4.9 6.3 1.28
Greece GR 270 25 0.8 0.8 1.04
Ireland IE 70 11 0.2 0.3 1.75
Italy IT 1939 259 5.4 8.2 1.51
Japan JP 4601 67 12.8 2.1 0.16
Netherlands NL 953 106 2.7 3.4 1.26
Norway NO 188 20 0.5 0.6 1.17
Portugal PT 42 2 0.1 0.1 0.51
Sweden SE 627 90 1.7 2.8 1.63
United Kingdom UK 2332 605 6.5 19.1 2.93
United States US 12428 1068 34.7 33.7 0.97
ISO digraphs are used to denote the countries in Figure 3.
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Figure 3 Ratio of countries’ presence among the UK cancer clinical
guideline references and their presence in world oncology research, 2000:
fractional counts. Country codes as listed in Table 1.
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Figure 2 RL distributions (cumulative percentages) for references on
cancer clinical guidelines (solid squares) and for oncology research in 2000
(open triangles).
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sand the United States have all shown a reducing presence in
oncology research, and a reducing presence in the guideline
references; Germany, on the other hand, has increased its presence
in both (but is still much undercited). France and Japan increased
their presence in both sets of papers, but it went down slightly
during the latest period.
Journal citation impact scores
The references cited tend to be published in high-impact journals.
Table 3 shows that in each RL grouping, the guideline references
are published in journals with a higher mean citation score (the
PCI, of the papers) than world oncology papers from the year 2000.
The overall mean is higher, too, at 19.9 cites in 5 years compared
with 13.4. The ‘superior performance’ of the guideline references
occurs because a large number of them are published in the high-
impact general journals, The Lancet (138 of them), New England
Journal of Medicine (133), British Medical Journal (78) and Journal
of the American Medical Association (50).
The funding of the UK cited references
Of the 796 UK papers, all but 6 were found and inspected to
determine their funding sources. These were taken both from the
addresses (as for some organisations this is an indication of
funding) and from the formal acknowledgements. For the purposes
of this analysis, funding sources were grouped into five main
sectors:
  UK government, both departments and agencies;
  UK private nonprofit, including collecting charities, endowed
foundations, hospital trustees, mixed (academic) and other
nonprofit. A subset of this sector is Cancer Research UK, and its
two predecessors, the Cancer Research Campaign and the
Imperial Cancer Research Fund;
  pharmaceutical industry, both domestic and foreign (it is often
difficult to distinguish as some subsidiaries have considerable
autonomy in the use of research funds), and including biotech
companies;
  nonpharma industry;
  no funding acknowledged.
The remaining funding organisations are foreign governmental
and private nonprofit sources, and international organisations,
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Figure 4 Scatter plot of the fractional count percentage presence of the
leading 26 UK postcode areas within the UK papers cited on the UK cancer
clinical guidelines plotted against their percentage presence in the UK
oncology research outputs in 2000. Codes: AB¼Aberdeen,
B¼Birmingham, BS¼Bristol, BT¼Belfast, CB¼Cambridge, CF¼Cardiff,
DD¼Dundee, EC¼London EC (St Bart’s), EH¼Edinburgh,
G¼Glasgow, HA¼Harrow, L¼Liverpool, LE¼Leicester, LS¼Leeds,
M¼Manchester, NE¼Newcastle upon Tyne, NG¼Nottingham,
NW¼London NW (Royal Free), OX¼Oxford, S¼Sheffield,
SE¼London SE (Guys, Kings and St Thomas’), SM¼Sutton and Cheam
(Institute of Cancer Research), SO¼Southampton, SW¼London SW
(St George’s), W¼London W (Imperial), WC¼London WC (UCL).
Table 2 Variation in time of the percentage presences of 10 leading countries in both the UK guideline references and the world oncology research;
fractional counts
Guideline references World oncology research
Period 1995–1997 1998–1999 2000–2001 2002–2005 1995–1997 1998–1999 2000–2001 2002–2005
AU 3.2 3.2 2.4 2.5 1.7 1.6 1.6 1.6
CA 5.3 4.7 4.5 4.0 3.0 3.0 2.9 2.8
DE 4.1 4.8 4.4 5.0 6.8 7.3 7.5 7.5
FR 5.9 7.4 6.6 6.0 5.1 5.2 4.7 4.6
IT 8.2 9.2 10.0 7.8 5.6 5.3 5.6 5.6
JP 1.7 2.6 2.7 2.5 11.2 12.6 12.4 11.6
NL 3.5 3.2 4.2 3.7 2.8 2.6 2.6 2.6
SE 3.4 2.3 3.1 3.1 2.1 1.8 1.8 1.6
UK 22.0 15.5 17.5 17.8 7.4 6.7 6.4 6.0
US 31.5 31.7 27.9 29.9 36.6 34.9 34.7 34.8
Table 3 Mean potential citation impact (PCI¼expected cites in 5 year
window) for world oncology papers for 2000 (oncology) and for guideline
references
RL
N of
oncology
papers
N of
guideline
references
PCI of
oncology
papers
PCI of
guideline
references
Clinical
1–1.5 12465 2316 9.6 21.5
1.5–2 4958 511 10.2 14.3
2–2.5 4747 217 10.0 12.1
2.5–3 2941 114 14.6 23.5
3–3.5 4976 38 18.9 24.8
Basic
3.5–4 5944 12 21.6 51.9
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Organization (WHO).
The funding sources vary with the RL of the papers: the more
clinical papers have fewer sources and the more basic papers have
more. Table 4 shows the analysis for the UK papers in oncology in
1999–2001, and Table 5 shows the results for the UK papers cited
on cancer clinical guidelines. For each RL group, an estimate has
been made of the funding that would have been expected had they
been typical of the UK cancer research, and in the last row there
are given the ratios of observed-to-expected numbers of papers
(integer counts) on the assumption that the cancer clinical
guideline citations are typical of oncology, but with due allowance
for the different RL distributions.
For example, the UK oncology papers in the first group (RL
from 1.0 to 1.5) have the UK government funding on 11.1% of
them, so it might be expected that there would be
0.111 544¼60.4 government-funded papers among the corre-
sponding group cited on cancer clinical guidelines. In fact, there
were 149 such papers, showing that many more are government
funded than might have been expected. When the totals for each of
the six groups are added, it can be seen that the observed number
of the UK government-funded papers is almost twice the predicted
number. The observed total is still higher ( 2.5) for the pharma
industry-funded papers, and a little lower for Cancer Research UK
papers ( 1.8), for nonpharma industry papers ( 1.6) and the
UK private nonprofit papers ( 1.3). Not surprisingly, there are
many fewer ‘unfunded’ papers, the ratio of observed-to-expected
numbers of papers being only just over half.
DISCUSSION
The UK cancer clinical guidelines are sufficient in number and
variety to provide a fair window on the impact of cancer research
on clinical practice, not only in the United Kingdom, but in other
leading countries, particularly in western Europe. We have seen
that almost all the references (88%) are to papers that are within
the subfield of cancer research. Because about one-third of the
research supported by Cancer Research UK, in common with that
of other medical research charities working in a particular disease
area, is out with this subfield (most of this would comprise basic
biology), it follows that little of this work can be expected to
influence clinical guidelines – hardly a surprising conclusion, but
nevertheless one that is worth stating.
Many of the guideline references are to papers in the US and the
UK general medical journals – The Journal of the American Medical
Association, New England Journal Medical, British Medical Journal
and The Lancet. This is one reason, but by no means the only one,
for the guideline references as a whole to be in high impact, and
therefore well known, journals. It appears that if researchers want
their work, particularly clinical trials, to be part of the evidence base
for clinical guidelines, then it is desirable for them to publish in
highly cited journals. Disproportionately, many of these papers will
have been funded by government or the pharmaceutical industry,
with charities also playing an enhanced role compared with cancer
research overall. This highlights one pitfall of national guidelines
in the context of research impact assessments; many important,
high quality clinical trials – either because they are early phase or
negative – will not make it into guidelines. The impact of research
on national clinical guidelines is just one parameter that can
describe the utility of health research (Kuruvilla et al, 2006).
Table 4 Funding of the UK oncology research papers in 1999–2001,
grouped by RL (integer counts); mean annual totals
RL: ONCOL N(A)
%o f
A GOV
GOV,
%P N P
PNP,
% CRUK
CRUK,
%
1–1.5 880 32 98 11 208 24 118 13
1.5–2 426 15 52 12 134 31 62 15
2–2.5 443 16 82 18 251 57 147 33
2.5–3 225 8 40 18 1247 55 55 24
3–3.5 330 12 77 23 189 57 99 30
3.5–4 452 16 163 36 300 66 163 36
Total 2756 100 511 19 1205 44 644 23
RL: ONCOL N(A) % of
A
Pharm Pharm,
%
Ind’y Ind’y,
%
None None,
%
1–1.5 880 32 53 6 25 3 527 60
1.5–2 426 15 39 9 17 4 200 47
2–2.5 443 16 71 16 20 4 96 22
2.5–3 225 8 22 10 70 3 48 21
3–3.5 330 12 43 13 17 5 43 13
3.5–4 452 16 65 15 20 4 37 8
Total 2756 100 294 11 106 4 950 35
A status¼inspected papers; CRUK¼Cancer Research UK; GOV¼the UK
government; Ind’y¼other industry; Pharm¼pharmaceutical industry; PNP¼UK
private nonprofit. Note: columns may not add correctly because of rounding.
Table 5 Funding of the UK papers cited by cancer clinical guidelines (G refs), grouped by RL (integer counts)
RL: G refs G refs % GOV-O GOV-C PNP-O PNP-C CRUK-O CRUK-C
1–1.5 544 69 149 60 198 129 142 73
1.5–2 127 16 26 16 49 40 39 19
2–2.5 83 11 13 15 46 47 33 28
2.5–3 19 2 4 3 13 11 9 5
3–3.5 13 2 2 3 5 7 3 4
3.5–4 1 0 1 0 1 1 0 0
Total 787 100 195 98 312 234 226 128
Obs/Calc 1.99 1.33 1.76
RL: G refs G refs % Pharm-O Pharm-C Indy-O Indy-C None-O None-C
1–1.5 544 69 116 33 25 16 156 326
1.5–2 127 16 19 12 8 5 40 60
2–2.5 83 11 18 13 8 4 21 18
2.5–3 19 2 0 2 1 1 4 4
3–3.5 13 2 3 2 0 1 3 2
3.5–4 1 0 0 0 0 0 0 0
Total 787 100 156 62 42 26 224 409
Obs/Calc 2.53 1.63 0.55
C¼calculated on basis of ONCOL papers; O¼observed number of papers. Columns may not add correctly because of rounding. Other column headings as in Table 4.
Impact of cancer research
G Lewison and R Sullivan
1948
British Journal of Cancer (2008) 98(12), 1944–1950 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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on guidelines, the big increase in the percentage of the papers
that acknowledge funding – whether from government, charities or
industry – is striking (Table 5). Many (37%) of these clinical
papers with RLs greater than 1.5 are reports of clinical trials, and
85% of the latter acknowledge funding compared with 71% of the
others. Cancer Research UK plays the biggest role, and supports
over one-third of these trials, more even than the pharmaceutical
industry as a whole, or the UK government.
The geographical analysis of the cited papers reveals that the UK
papers have a threefold higher presence among them than in world
cancer research. In part, this reflects the differences in cancer
management between countries. Such overcitation also occurs on
other scientific papers, so it is hardly surprising that it was found
here. It might be expected that the UK guidelines, which aim to
show which treatments are cost-effective, would reflect in
particular the different financial basis of health-care provision in
this country compared with that elsewhere, and so papers
concerned with economics and costs would be even more overcited
if they were from the United Kingdom. In fact, this does occur, but
to a very minor extent (22% from the United Kingdom compared
with 19% overall; the difference not being significant).
The distribution of the cited papers within the United Kingdom
differs from what might have been expected based purely on
overall numbers and on the extent to which the cities carry out
clinical observation rather than basic research. The simple
comparison of Figure 4 needs also to take account of the mean
RL of papers from each area, and, when this is done (Figure 5), a
different pattern emerges, with EH¼Edinburgh, OX¼Oxford and
CB¼Cambridge forming an axis of excellence (on this indicator)
and other areas’ output being less cited on guidelines. The distance
of the spots from this axis gives one indicator of the performance
of the different centres, an imperfect one to be sure, as there will be
other confounding factors not considered here, but nevertheless a
useful complement to the traditional bibliometric criterion based
purely on citation counts in the scientific literature.
There are in the database enough cited papers from a few other
countries to enable a similar evaluation to be carried out for them.
However, these data are inevitably skewed by being viewed
through the prism of the UK clinical recommendations. It would
be highly desirable to complement them with the results of similar
exercises carried out in other countries with extensive sets of
clinical guidelines, or at a European or international level. Then,
provided the data were collected in exactly the same way, they
could be pooled and a more international perspective on the utility
of cancer research would emerge that research evaluators could
employ. Such an activity could appropriately be coordinated by the
European Cancer Managers’ Research Forum, with all data
contributors having also the right to gain access to the data
provided by workers in other countries.
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